GSK stock gains on Berenberg upgrade and steady pipeline momentum

Published on 09/18/2026 at 22:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock received an upgrade to Buy from Berenberg on September 18, 2026, with the price target lifted from GBP 20 to GBP 22. The shares recently closed around GBP 19.00 in London, leaving upside versus the new target and peers in the pharma sector.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK plc stock (ISIN GB0009252882) is drawing renewed investor attention after analysts at Berenberg lifted their recommendation to Buy and raised their target price from GBP 20 to GBP 22 on September 18, 2026, citing stronger business-development activity and pipeline momentum as key drivers.

Berenberg upgrade shifts sentiment

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development transactions and strengthening pipeline momentum support a better long-term growth profile.

The new GBP 22 target represents roughly a 10 percent increase from the previous GBP 20 level, and implies upside of about 16 percent versus a recent London closing price of around GBP 19.00, based on data cited by Zonebourse.

Consensus and valuation context

Berenberg's more positive stance comes as other banks remain cautious: Deutsche Bank continues to rate GSK as Neutral or Hold with a price target around GBP 20, according to finanzen.ch on September 18, 2026.

The average broker target price on GSK stands at about GBP 21.71 per share, based on a recent overview cited by MarketScreener, placing Berenberg's GBP 22 view modestly above consensus.

Risk factors and peer comparison

As noted by Foreign Policy Journal on September 18, 2026, GSK currently trades at approximately 15.5 times earnings, compared with a broader pharmaceuticals industry average of around 21.8 times, highlighting a valuation discount that persists despite a roughly 58 percent share-price gain over the past five years.

The same analysis points to ongoing litigation and product-concentration risks as key factors behind the discount, even as the company invests in vaccines and specialty medicines to diversify its revenue base, providing investors with both opportunity and caution signals.

Stock price and trading data

GSK's primary listing is on the London Stock Exchange under the ticker GSK, where the shares recently closed at about GBP 19.00 with the stock quoted around 1,881 GBX in intraday trading on September 18, 2026, per indicative Cboe Europe data referenced by Zonebourse.